Top Markets
#1 Siren Siren +34.73%
#2 Wiki Cat Wiki Cat +30.30%
#3 Ribbita by Virtuals Ribbita by Virtuals +19.62%
#4 Bitway Bitway +19.40%
#5 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +17.45%
#6 PulseChain PulseChain +16.92%
#7 TRIA TRIA +16.78%
#8 Velvet Velvet +16.02%
#9 The Grays Currency The Grays Currency +15.46%
#10 Wrapped Pulse Wrapped Pulse +15.27%
Coin of the day
Siren Siren
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Synthetic Biologics, Inc. Synthetic Biologics, Inc.

Synthetic Biologics, Inc.

SYN
Classifica tra le azioni #30607
Synthetic Biologics, Inc. is a clinical-stage biotechnology firm focused on... Synthetic Biologics, Inc. is a clinical-stage biotechnology firm focused on creating treatments for illnesses with significant unmet medical demands. Among its leading product candidates is SYN-004, engineered to neutralize common intravenous beta-lactam antibiotics within the digestive system. This aims to safeguard the gut microbiome, prevent Clostridium difficile infections (CDI), curb the proliferation of harmful bacteria, combat antimicrobial resistance (AMR), and mitigate acute graft-versus-host-disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplants. Another key asset is SYN-020, an orally administered recombinant formulation of intestinal alkaline phosphatase, intended to address both localized gastrointestinal and systemic conditions. The company is also advancing VCN-01, a therapeutic candidate for various cancers, including pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. Additional clinical-stage programs include SYN-006, targeting the prevention of aGVHD and infections from carbapenem-resistant enterococci; SYN-007, designed to avert antibiotic-associated diarrhea linked to oral beta-lactam antibiotics; SYN-005, for the prevention and treatment of whooping cough (pertussis); and VCN-11, another cancer therapeutic. Synthetic Biologics maintains partnerships with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. Furthermore, a clinical trial agreement with Washington University School of Medicine in St. Louis supports a Phase 1b/2a clinical trial for SYN-004. The company's main operations are based in Rockville, Maryland.
Prezzo delle azioni
$1.02
Ultima sincronizzazione: 2022-10-13
Capitalizzazione di mercato
$16.16M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Synthetic Biologics, Inc. (SYN)

Categoria

Healthcare
Storico del prezzo dell'azione per Synthetic Biologics, Inc. (SYN)
Prezzo di chiusura più alto: $1.05 il 2022-10-01

Prezzo di chiusura più basso: $838.79 il 2012-02-01
Storico del prezzo dell'azione di Synthetic Biologics, Inc. dal 2012 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2022 -66.74%
2021 -13.70%
2020 -18.74%
2019 -28.68%
2018 -96.72%
2017 -33.18%
2016 -66.52%
2015 62.87%
2014 20.10%
2013 -27.54%
2012 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $527.89 35.40%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $996.61 50.70%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $111.31 -36.83%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $735.86 6.87%
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $257.75 13.01%
BE